Research ArticleGeneral Nuclear Medicine
Absolute Organ Activity Estimated by Five Different Methods of Background Correction
Wilhelmina C.A.M. Buijs, Jeffry A. Siegel, Otto C. Boerman and Frans H.M. Corstens
Journal of Nuclear Medicine December 1998, 39 (12) 2167-2172;
Wilhelmina C.A.M. Buijs
Jeffry A. Siegel
Otto C. Boerman
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Absolute Organ Activity Estimated by Five Different Methods of Background Correction
Wilhelmina C.A.M. Buijs, Jeffry A. Siegel, Otto C. Boerman, Frans H.M. Corstens
Journal of Nuclear Medicine Dec 1998, 39 (12) 2167-2172;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Influence of Vitamin C on Salivary Absorbed Dose of 131I in Thyroid Cancer Patients: A Prospective, Randomized, Single-Blind, Controlled Trial
- 99mTc-Labeled Interleukin 8 for the Scintigraphic Detection of Infection and Inflammation: First Clinical Evaluation
- Renal Uptake of Radiolabeled Octreotide in Human Subjects Is Efficiently Inhibited by Succinylated Gelatin
- Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response
- Evaluation of Accuracy in Activity Calculations for the Conjugate View Method from Monte Carlo Simulated Scintillation Camera Images Using Experimental Data in an Anthropomorphic Phantom
- Dosimetric Analysis of Radioimmunotherapy with 186Re-Labeled Bivatuzumab in Patients with Head and Neck Cancer
- Targeting of Metastatic Renal Cell Carcinoma with the Chimeric Monoclonal Antibody G250 Labeled with 131I or 111In: An Intrapatient Comparison
- Safety, Biodistribution, and Dosimetry of 99mTc-HYNIC-Annexin V, a Novel Human Recombinant Annexin V for Human Application
- An Activity Quantification Method Based on Registration of CT and Whole-Body Scintillation Camera Images, with Application to 131I
- Patient Dosimetry of Intravenously Administered 99mTc-Annexin V
- Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck